Dariohealth corp. (DRIO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Revenues

1,667

-

1,868

-

2,242

-

1,879

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenues

-

-

-

1,651

-

-

-

2,059

1,756

1,578

1,375

1,210

1,007

838

728

669

568

308

273

175

67

51

0

0

0

-

0

0

-

-

-

-

-

Cost of revenues

888

958

995

1,325

1,684

1,477

1,411

1,537

1,204

-

1,099

850

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

901

1,216

652

826

670

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

404

410

297

663

585

605

421

-

0

0

-

-

-

-

-

Gross profit

779

840

873

326

558

223

468

522

552

569

276

360

106

-647

76

-157

-102

-259

-131

-235

-230

-1,101

-585

-605

-421

-

0

0

-

-

-

-

-

Operating expenses:
Research and development

1,231

840

859

991

1,002

927

997

1,010

742

847

797

1,184

469

577

659

521

397

574

667

441

883

734

769

1,333

1,107

1,743

1,078

1,416

675

489

391

449

171

Sales and marketing

4,091

2,323

1,865

2,993

3,946

3,260

2,816

2,369

1,864

2,000

1,677

2,205

1,825

1,545

1,533

1,142

519

399

417

262

252

152

252

373

286

430

763

664

497

167

128

0

0

General and administrative

5,571

1,858

948

1,704

973

962

709

2,936

861

839

781

1,089

2,017

1,065

605

803

905

630

1,332

574

412

593

901

1,292

854

1,479

1,397

1,516

1,904

933

503

417

323

Total operating expenses

10,893

5,021

3,672

5,688

5,921

5,149

4,522

6,315

3,467

3,686

3,255

4,478

4,311

3,187

2,797

2,466

1,821

1,603

2,416

1,277

1,547

1,479

1,922

2,998

2,247

-

3,238

3,596

-

-

-

-

-

Operating loss

-10,114

-4,181

-2,799

-5,362

-5,363

-4,926

-4,054

-5,793

-2,915

-3,117

-2,979

-4,118

-4,205

-3,834

-2,721

-2,623

-1,923

-1,862

-2,547

-1,512

-1,777

-2,580

-2,507

-3,603

-2,668

-3,652

-3,238

-3,596

-3,076

-1,590

-1,023

-866

-494

Revaluation of warrants

-

-

-

0

-

0

0

0

-1

-1

-1

-25

1,195

668

-2,788

1,428

432

-194

-753

526

-150

950

-2,606

-396

-142

-

-

-

-

-

-

-

-

Revaluation of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-192

-1,664

-2,136

400

-2,033

5

21

Issuance cost related to warrants to investors and service provider

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Financial expense, net

-

-

-6

-20

-

-57

-9

-45

-5

-149

5

1

-13

651

-678

-6

-13

-3

-35

34

-11

-32

-3,176

-47

-458

6

-41

-26

-15

-2

0

-6

-97

Total financial expenses (income), net

222

8

-6

-20

-13

-57

-9

-45

-4

-148

6

26

-1,208

-17

2,110

-1,434

-445

191

718

-492

139

-982

-570

349

-316

3,705

-233

-1,690

-2,151

397

-2,032

-0

-76

Net loss

-9,892

-4,173

-2,805

-5,382

-5,376

-4,983

-4,063

-5,838

-2,919

-3,265

-2,973

-4,092

-5,413

-3,851

-611

-4,057

-2,368

-1,671

-1,829

-2,004

-1,638

-3,562

-3,077

-3,254

-2,984

53

-3,471

-5,286

-5,227

-1,192

-3,056

-867

-570

Deemed dividend related to warrant exchange agreement

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend

-1,275

-

-

0

-

-

-

-493

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend related to May 2015 exchange agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

154

-

-

0

-

-

-

-

-

-

-

-

-

-

Deemed dividend related to Series A Preferred Stock exchange agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

455

-

0

-

-

-

279

0

-

-

0

-

-

-

-

-

-

Deemed dividend related to extension of July 2015 Series A warrants in July 2016

-

-

-

-

-

-

-

-

-

-

-

-

-

-

265

-

-

0

0

0

0

-

2,977

-

-

-

0

-

-

-

-

-

-

Net loss attributable to holders of Common Stock

-11,167

-7,328

-2,805

-5,382

-5,376

-4,983

-4,063

-6,331

-2,919

-3,520

-2,973

-4,092

-5,413

-3,851

-876

-4,057

-2,823

-1,671

-1,829

-2,158

-1,638

-

-6,333

-3,254

-

-

-3,471

-

-

-

-

-

-

Net loss per share:
Basic and diluted net loss per share

-1.57

11.11

-0.06

-0.13

-2.92

16.32

-0.17

-0.32

-0.20

3.12

-0.30

-0.43

-0.75

3.74

-0.15

-0.73

-0.77

7.39

-0.90

-1.26

-1.39

-

-

-

-0.70

-

-

-

-

0.83

-0.25

-0.07

-0.05

Weighted average number of Common Stock used in computing basic and diluted net loss per share **)

3,090

-86,024

50,730

42,519

1,839

-53,595

23,533

19,801

14,943

11,845

9,950

9,521

7,195

5,866

5,705

5,587

3,652

2,655

2,079

1,680

1,175

-

-

-

4,254

-

-

-

-

14,474

12,167

11,957

10,899

Basic loss per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.66

-0.14

-

-

-0.85

-0.29

-0.35

-

-

-

-

Weighted average number of common stock used in computing basic net loss per share (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,610

22,985

-

-

3,994

18,327

14,808,563

-

-

-

-

Diluted loss per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.66

-0.15

-

-

-0.85

-0.29

-0.35

-

-

-

-

Weighted average number of common stock used in computing diluted net loss per share (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,610

23,202

-

-

3,994

18,327

14,808

-

-

-

-